Inactivating somatic mutations of liver kinase B1 (LKB1) are frequently reported in non-small-cell lung cancer (NSCLC), malignant melanoma, and cervical carcinoma.[7–9] However, the results are controversial. This evidence concerns the gene STK11 and non-small cell lung carcinoma.